GlaxoSmithKline’s newest approved asthma drug provide pediatric asthma maintenance to a field lacking convenient options. What is there to look forward to?
The inhaled corticosteroid ozone was recently approved for the maintenance of asthma and children as young as five years old and this is also great news because it gives us confidence to be able to prescribe these medications and children for increasing their asthma control the benefit of that is we hope in the in the long run will help to reduce their oral steroid
Dosage needs as well as just maintain their disease in a way such that we preserve their lung function as we go as they grow through their development one of the downsides of asthma and having asthma flares especially in children is the loss of lung function over time and so in order to protect that response and preserve lung function and as well as all the other
Benefits that come from asthma control and children having a once-daily medication is is beneficial and as we know it’s it’s hard to do studies and children it’s hard to get children to take medications so if we can find a simple way of delivering medications once a day in a way that will help to reduce the burden of symptoms and other effects then i think we’re on
The right track the current field of pediatric asthma is very exciting because it has now i think finally embraced the multiple dimensions of what is contributing to poor asthma and children and i think this involves in a greater appreciation of all the environmental factors that have influenced the development of asthma as well as the progression of asthma we have
A greater understanding of environmental influences even as early as during the gestational period during pregnancy and really getting a greater appreciation that those factors heavily influence what child outcomes are going to be later in life one of the bigger challenges that we’ve had has been childhood obesity and we know that obesity rates have risen across
The population but specifically in children and its impact on asthma is yet to be seen but we do think that there’s relationships between child obesity rates as well as asthma rates and trying to disentangle how we can better address this is still up in the air and a lot of the therapies that we’ve been discussing so far have been looking at more individual and
Targeted approaches trying to understand which kids are going to benefit from certain therapies we’ve had the evolution of what we call biologic therapy which are steroid sparing therapy and trying to better understand which child would benefit from these is also going to be very important so i think for the first time we’re getting an expansive understanding of
All the other factors that are playing a role in asthma and then trying to target each of them in a global fashion
Transcribed from video
Sonali Bose, MD: Fluticasone Furoate and Other Therapies for Pediatric Asthma By HCPLive
